Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography.
A new UV spectrophotometric method (UV method) and a reversed phase liquid chromatographic method (LC method) for the quantitative estimation of celecoxib, a selective COX-2 inhibitor, in pure form and in solid dosage form were developed in the present study. The linear regression equations obtained by least square regression method, were Abs=4.949 x 10(-2).Conc. (in microg/ml)+1.110 x 10(-2) for the UV method and Area under the curve=5.340 x 10(1).Conc. (in ng/ml)+3.144 x 10(2) for the LC method, respectively. The detection limit, as per the error propagation theory, was found to be 0.26 microg/ml and 25 ng/ml, respectively, for the UV and LC methods. The developed methods were employed with a high degree of precision and accuracy for the estimation of total drug content in three commercial capsule formulations of celecoxib. The results of analysis were treated statistically, as per International Conference on Harmonisation (ICH) guidelines for validation of analytical procedures, and by recovery studies. The results were found to be accurate, reproducible and free from interference and better than the earlier reported methods.
Saha
R N
RN
Pharmacy Group, Birla Institute of Technology and Science, Pilani 333 031, India. rnsaha@bits-pilani.ac.in
Sajeev
C
C
Jadhav
P R
PR
Patil
S P
SP
Srinivasan
N
N
D002138:Calibration; D002214:Capsules; D000068579:Celecoxib; D002853:Chromatography, Liquid; D016861:Cyclooxygenase Inhibitors / Q000032:analysis*; D016014:Linear Models; D019999:Pharmaceutical Solutions; D011720:Pyrazoles; D012015:Reference Standards; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet; D013449:Sulfonamides / Q000032:analysis*
D002214:Capsules; D016861:Cyclooxygenase Inhibitors; D019999:Pharmaceutical Solutions; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib